KalVista Pharmaceuticals, Inc. KALV 深 滬
已收盤 10-03 16:00:00 美东时间
11.85
+0.100
+0.85%
華盛通- 最 高11.93
- 今 開11.81
- 成交量 173.67万股
- 最 低 11.6037
- 昨 收 11.75
- 總市值 5.99亿
- 52周最高 17.28
- 市盈率 靜 --
- 換手率 3.44%
- 52周最低 7.30
- 委 比 72.83%
- 總股本 5052.33万
- 歷史最高 45.00
- 量 比 1.26
- 振 幅 2.78%
- 歷史最低 4.12
- 每 手 1
- 風險率 1.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多KalVista Pharmaceuticals Completes Convertible Notes Sale
The latest announcement is out from KalVista Pharmaceuticals ( ($KALV) ). On Se...
09-30 04:45
Ionis reports promising data from study of Alexander disease therapy
Ionis Pharmaceuticals (NASDAQ:IONS) has reported promising results from a pivotal study of its experimental medicine, zilganersen, for the treatment of Alexander disease, a rare and progressive neurol...
09-22 21:09
KalVista Pharma Says EC And Swissmedic Approve EKTERLY, Oral Plasma Kallikrein Inhibitor, For Symptomatic Treatment Of Acute Attacks Of HAE In Adults
First European launch of EKTERLY expected in Germany Q4 2025EKTERLY now approved in the US, EU, UK and Switzerland with additional regulatory applications under review in key global marketsKalVista Pharmaceuticals, Inc.
09-19 19:02
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
JMP Securities Maintains Market Outperform on KalVista Pharmaceuticals, Raises Price Target to $28
JMP Securities analyst Jonathan Wolleben maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Market Outperform and raises the price target from $27 to $28.
09-12 19:05
KalVista Pharmaceuticals Reports Strong Start for EKTERLY Launch
KalVista Pharmaceuticals, Inc. ( ($KALV) ) has released its Q1 earnings. Here i...
09-12 11:52
KalVista Pharmaceuticals GAAP EPS of -$1.12 misses by $0.17, revenue of $1.43M misses by $0.66M
KalVista Pharmaceuticals press release (NASDAQ:KALV): Q1 GAAP EPS of -$1.12 misses by $0.17. Revenue of $1.43M misses by $0.66M. As of July 31, 2025, the Company had cash, cash equivalents and marketa...
09-11 19:03
KalVista Pharma Q1 EPS $(1.12) Misses $(0.95) Estimate, Sales $1.426M Miss $2.089M Estimate
KalVista Pharma (NASDAQ:KALV) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.95) by 17.28 percent. This is a 28.74 percent decrease over losses of $(0.87) per share from
09-11 19:01
Earnings Scheduled For September 11, 2025
Companies Reporting Before The Bell • Kroger (NYSE:KR) is expected to report qu...
09-11 16:32
KalVista Pharma's Earnings: A Preview
KalVista Pharma (NASDAQ:KALV) will release its quarterly earnings report on Thu...
09-10 22:01
